RCS - Byotrol PLC - Launch of CHEMGENE MEDLAB into human healthcare

ByotrolAnnouncement

29/08/2023 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230829:nRSc6502Ka&default-theme=true

RNS Number : 6502K  Byotrol PLC  29 August 2023

RNS REACH

 

 

Byotrol Plc

("Byotrol" or the "Company")

 

Launch of CHEMGENE MEDLAB into human healthcare

 

Byotrol plc (AIM:BYOT), the specialist infection prevention and control
company, is pleased to announce the launch into human healthcare of its
next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB.

 

The CHEMGENE brand, previously marketed by Medimark Scientific Ltd and
acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted
choice for disinfecting surfaces and equipment across emergency services,
laboratories, and human health organisations.

 

This new formulation is designed for market-leading, broad-spectrum efficacy,
low toxicity and regulatory approval across the UK and EU under the
increasingly stringent biocidal regulations.

 

CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against
bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy
against:

 

·    The ESKAPE group of bacteria, targeted in healthcare environments for
their multi-drug resistance, and virulence.

·    Critical viruses, including Norovirus, Adenovirus, and the Vaccinia
virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV,
Hepatitis B & C, and Herpes Simplex virus.

·    Emerging fungus Candida auris, known for its global health threat due
to multi-drug resistance and ease of transmission within healthcare settings.

 

CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous
microbiological testing to the latest European efficacy test methodologies,
including stringent medical standards that simulate high soil conditions akin
to the presence of blood and other organic fluids during disinfection.

 

For detailed information about the forthcoming CHEMGENE MEDLAB Multi-Surface
Disinfectants range and supporting product documentation please visit our
commercial website, www.byotrol.com.

 

Vivan Pinto, CEO of Byotrol, states:

 

"The launch of Byotrol's new and improved CHEMGENE MEDLAB range is a huge step
forward in our plans to future-proof our portfolio for EU and UK BPR
regulatory approvals. It is the second big recent step for us in healthcare
markets, following the successful launch of ANIGENE into animal health markets
last year.  We are very excited about its potential."

 

 

 

For further information contact:

 

 Byotrol Plc

 Vivan Pinto, Chief Executive Officer                                                 +44 (0)1925 742 000

 Chris Sedwell, Chief Financial Officer

 finnCap Limited (Nominated Adviser and Broker)                                       +44 (0)20 7220 0500
 Geoff Nash/George Dollemore - Corporate Finance

 Nigel Birks/Harriet Ward - ECM

 Flagstaff Strategic and Investor Communications                                      +44 (0)20 7129 1474
 Tim Thompson/Andrea Seymour/Fergus Mellon                                            byotrol@flagstaffcomms.com (mailto:byotrol@flagstaffcomms.com)

 

 

 

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and
control company, operating globally in the Healthcare, Industrial, Food and
Consumer sectors, providing low toxicity products with a broad-based and
targeted efficacy across all microbial classes; bacteria, viruses (including
coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing
products, where they can significantly improve their performance, especially
in personal hygiene, domestic and industrial disinfection, odour control, food
production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and
cleaner lives for everyone.

 

For more investor information, go to byotrolplc.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAXPNALNDEEA